Pancreatitis Treated with Didanosine and Tenofovir Disoproxil Fumarate | Zendy

Jennifer Blanchard | Zendy; Michael Wohlfeiler | Zendy; Alejandra Cañas | Zendy; Karen E. King | Zendy; J Tyler Lonergan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pancreatitis Treated with Didanosine and Tenofovir Disoproxil Fumarate

Author(s) -

Jennifer Blanchard,

Michael Wohlfeiler,

Alejandra Cañas,

Karen E. King,

J Tyler Lonergan

Publication year - 2003

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/376991

Subject(s) - didanosine , medicine , pancreatitis , tenofovir , rotavirus , pharmacology , drug , gastroenterology , human immunodeficiency virus (hiv) , virology , viral disease , sida , virus

Pancreatitis occurs in up to 7% of patients infected with human immunodeficiency virus who are treated with standard doses of didanosine. Tenofovir disoproxil fumarate increases the plasma levels of didanosine and, thus, the combination of these agents may increase the risk of pancreatitis. Four cases of pancreatitis that occurred during administration of this drug combination are examined, including 1 that resulted in death.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research